Concepedia

Karin Kemsley

KK

Statistics

Publications

4

Citations

570

H-Index

4

Active since

2008

Affiliations

AstraZeneca (United Kingdom)(Current)

Karin Kemsley is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and oncology.

Publications per year

2008–2011

4

Publications

4

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

John M. Kirkwood, Lars Bastholt, Caroline Robert et al. · Clinical Cancer Research · 2011 · 274 citations · Full text

Medicine, Oncology, Pharmacology +13

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study

Reinhard Dummer, Caroline Robert, Paul B. Chapman et al. · Journal of Clinical Oncology · 2008 · 132 citations

Medicine, Pharmacology, Pharmacotherapy +14

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

Gillian Ellison, Maria Orr, Karin Kemsley et al. · British Journal of Cancer · 2009 · 101 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.

Rebecca Dent, Geoffrey J. Lindeman, M. Clemons et al. · Journal of Clinical Oncology · 2010 · 63 citations

Medicine, Oncology, Pharmacology +15

1–4 of 4